Trung Huynh
Stock Analyst at RBC Capital
(4.66)
# 177
Out of 5,154 analysts
62
Total ratings
66.67%
Success rate
22.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Initiates: Underperform | $25 | $27.05 | -7.58% | 7 | Feb 25, 2026 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,250 | $990.33 | +26.22% | 11 | Feb 25, 2026 | |
| BMY Bristol-Myers Squibb Company | Initiates: Sector Perform | $60 | $60.29 | -0.48% | 6 | Feb 25, 2026 | |
| ABBV AbbVie | Initiates: Outperform | $260 | $230.11 | +12.99% | 2 | Feb 25, 2026 | |
| MRK Merck & Co. | Initiates: Outperform | $142 | $115.79 | +22.64% | 5 | Feb 25, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $595 → $660 | $759.86 | -13.14% | 5 | Nov 7, 2025 | |
| INSM Insmed | Maintains: Buy | $194 → $223 | $140.13 | +59.14% | 9 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $1.38 | +1,711.59% | 3 | Aug 15, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $369.53 | -14.22% | 6 | Aug 6, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $29.43 | +29.12% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $7 | $3.17 | +120.82% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $8.10 | +60.49% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $240.40 | -27.20% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.59 | - | 1 | Mar 23, 2021 |
Pfizer
Feb 25, 2026
Initiates: Underperform
Price Target: $25
Current: $27.05
Upside: -7.58%
Eli Lilly and Company
Feb 25, 2026
Initiates: Outperform
Price Target: $1,250
Current: $990.33
Upside: +26.22%
Bristol-Myers Squibb Company
Feb 25, 2026
Initiates: Sector Perform
Price Target: $60
Current: $60.29
Upside: -0.48%
AbbVie
Feb 25, 2026
Initiates: Outperform
Price Target: $260
Current: $230.11
Upside: +12.99%
Merck & Co.
Feb 25, 2026
Initiates: Outperform
Price Target: $142
Current: $115.79
Upside: +22.64%
Regeneron Pharmaceuticals
Nov 7, 2025
Maintains: Neutral
Price Target: $595 → $660
Current: $759.86
Upside: -13.14%
Insmed
Oct 31, 2025
Maintains: Buy
Price Target: $194 → $223
Current: $140.13
Upside: +59.14%
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $1.38
Upside: +1,711.59%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $369.53
Upside: -14.22%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $29.43
Upside: +29.12%
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $3.17
Upside: +120.82%
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $8.10
Upside: +60.49%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $240.40
Upside: -27.20%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $8.59
Upside: -